Handbook of Genetic Counseling/Osteosarcoma and Li-Fraumeni Syndrome
Osteosarcoma and Li-Fraumeni Syndrome
Contracting
edit- What concerns do you have for yourself or for your family?
- What questions do you have?
- Overview of agenda
- Elicit medical history
- Review family history
- Discuss genetics, testing, treatment and management
Osteosarcoma Background
edit- Most common type of bone cancer
- Arises in osteoid tissue in bones
- Most common in knees, upper legs, and upper arms
- Commonly affects people from ages 10-25
- Accounts for about 5% of childhood tumors
- 50% form in bones around knee
- Only about 30% of patients with localized tumors survive free of relapse
- Symptoms of bone cancer
- Pain is most common symptom
- Other symptoms depend on location and size of tumor
- Tumors in or near joints may cause swelling or tenderness
- Can interfere with normal ability to move
- May weaken bones and make fractures more likely
- General symptoms include fatigue, fever, weight loss, and anemia
- Diagnosis
- Alkaline phosphatase assay
- Blood test to determine enzyme levels
- Large amounts of alkaline phosphatase found in blood when cells of bone tissue are active
- During childhood growth
- During mending of broken bone
- When tumor causes production of abnormal bone tissue
- X-rays show location, size, and shape of tumor
- Bone scan, CT, MRI, or angiogram may be recommended if X-ray suggests that a tumor is cancerous
- Biopsy needed to determine for sure if tumor is cancer
- Needle biopsy - make small hole in bone and remove tissue sample from tumor with needle-like instrument
- Incisional biopsy - cut into tumor and remove sample of tissue
- No staging system for osteosarcoma so use general terms
- Localized
- Metastatic - most often to lungs or other bones (20% of patients)
- Recurrence - most often in the lungs (5 year survival is 20-40% following surgery)
- Alkaline phosphatase assay
- Treatment
- Depends on type, size, location, and stage of cancer
- Surgery
- Amputation of limb necessary in some cases
- Pre or post-operative chemotherapy has improved success of limb-sparing surgery
- May remove only cancerous section of bone and replace it with prosthesis
- Chemotherapy and radiation may be used alone or together
- Tumors are generally resistant to radiation
- Degree of necrosis following chemotherapy predicts prognosis
- Various clinical trials for surgeries, radiation therapies, and chemotherapies
- Risk factors for bone cancers
- Radiation or chemotherapy treatment in children or young adults for other conditions
- Adults with Paget's disease are at increased risk for osteosarcoma
- Hereditary factors
Li Fraumeni Syndrome Overview
edit- Cancer predisposition syndrome
- Associated with soft-tissue sarcomas, breast cancer, leukemia, osteosarcoma, melanoma, and cancer of the colon, pancreas, adrenal cortex, and brain
- Increases risk for development of cancers
- Diagnosis is made clinically and genetic testing is available
Genetic Etiology
edit- Due to mutation in TP53 gene on 17p13 that codes for TP53 protein in more than 50% of cases
- Tumor suppressor gene nicknamed "guardian of the genome"
- Acts as checkpoint control following DNA damage by delaying cell cycle progression until damaged DNA is repaired or cell commits to apoptosis
- Activates downstream genes to repair DNA
- Signals molecule to confirm damage and proceed with apoptosis
- Arrests cell cycle by mediating RB pathway
- CHEK2 gene at 22q12.1 also associated with Li-Fraumeni syndrome
- Reported in only a few families thus far
- Putative tumor suppressor gene
- Lies in TP53 pathway
- One of checkpoint genes activated in response to DNA damage by phorsphorylating p53
- Not known if cancer risks are different than those due to TP53 mutations
- Mutations in this gene appear to be most common in osteosarcomas
- Autosomal dominant inheritance
- Offspring of affected individuals have 50% chance of inheriting mutation
- Most individuals diagnosed have an affected parent
- De novo mutation rate unknown
- Fewer than 400 families reported worldwide
- Association of malignancies with TP53 mutations
- Less than 1% of all breast cancers
- 2-10% of childhood brain tumors
- 50-100% of childhood adrenocortical carcinomas
- 2-3% of osteosarcomas
- 9% of rhabdomyosarcomas
- 7-20% of multiple primaries occurring at young ages
- Penetrance
- May be as high as 90%
- About 25% of cancers occur before age 18
- About 50% of individuals have malignancy by age 40
- About 90% of individuals have malignancy by age 70
- Different studies give different numbers - may be genetic heterogeneity
Clinical Features
edit- Predisposes to a number of different types of tumors
- Osteosarcomas (23/151)
- Soft-tissue sarcomas (32/151)
- Pre-menopausal breast cancers (36/151)
- Brain tumors - neuroblastoma commonly (14/151)
- Adrenal cortical tumors (4/151)
- Leukemia - particularly acute leukemia (9/151)
- Also associated with excess rates of other cancers
- Melanoma
- Stomach cancer
- Colon cancer
- Pancreatic cancer
- Esophageal cancer
- Gonadal germ cell tumors diagnosed at young ages
- Wilm's tumor
- Adult women have higher cancer risk than men because of high frequency of breast cancer
- Also increases risk to develop multiple primary cancers
- Up to 50% may develop second cancer
- 4% develop third cancer
- 2% develop four cancers
- Survivors of childhood cancer have greatest risk to develop another primary
- Radiation exposure appears to increase risk of second cancer
- Genotype-phenotype correlation
- R337H mutations associate with development of childhood adrenocortical carcinoma as low penetrance allele
- 13964gc mutation in intron 6 in series of patients with breast cancer as low penetrance allele
Diagnosis
edit- Clinical diagnostic criteria (LFS)
- Proband with sarcoma diagnosed under 45 years of age
- First-degree relative with any cancer under 45 years of age
- Third family member who is first- or second-degree relative with cancer under 45 or sarcoma at any age
- Li-Fraumeni-like syndrome (LFL)
- Share some, but not all features of LFS
- Birch's definition
- Proband with any childhood cancer or sarcoma, brain tumor, or adrenal cortical tumor diagnosed under 45 years of age
- First- or second-degree relative with a typical LFS cancer at any age
- Additional first- or second-degree relative with any cancer under the age of 60
- Eele's definition
- Two first- or second-degree relatives with LFS-related malignancies
- Can occur at any age
- Molecular genetic testing
- Identifies mutations in TP53 gene in about 70% of patients with LFS and 8-22% of families with LFL
- DNA sequencing
- Available clinically
- Identifies mutations in about 75% of families
- About 80% of identifiable mutations are in exons 5-8 so testing is often limited to only these exons
- Full gene sequencing and protein function for novel missense mutations generally only offered on research basis
- Chip-based DNA sequencing
- Available on research basis only
- Detects most of common single base pair mutations that have been identified
- Sensitivity of 90-98% depending on how much of coding region is sequenced
- Can test asymptomatic individuals once mutation is identified in the family
- Cannot predict age of onset, severity, type of cancer, or rate of preogression
- Lack of proven surveillance or prevention so not justified for management but may be useful for reproductive, financial, and career planning or peace of mind
- Testing has been confined to individuals 18 and older since no proven management options
- Prenatal testing is possible if mutation identified in family but requires careful genetic counseling
- Potential risks of testing
- May not be covered by insurance
- Possible problems with health, life, and disability insurance coverage
- Possible employment and educational discrimination
- Changes in social and family interaction
- Implications for other at-risk family members
- Limitations in management options
- Potential benefits of testing
- Explanation for frequent/rare occurrence of cancer in family
- Clarification of risk/relief if individual tests negative for known mutation
- Help make decisions regarding medical management or life decisions
- Clinical molecular testing
- City of Hope
- Sequencing of coding exons 2-11 and intron junctions
- Sensitivity estimated to be greater than 95% for point mutations
- Requires 6 cc of whole blood in yellow or lavender topped tube
- Full mutation analysis - $450, known mutation analysis $250
- Turn-around time is 4 weeks
- University of Pennsylvania
- Conformation sensitive gel electrophoresis (CSGE)
- Shows differences in 2 alleles as small as single base substitution, insertion, deletion
- Sensitivity estimated to be greater than 95% in coding sequence
- Turn-around time is 4 weeks
- Fairview Molecular Diagnostic Laboratory
- Sequencing analysis
- Requires 15 ml blood in yellow topped tube
- Turn-around time is 4-8 weeks
- City of Hope
Management
edit- No surveillance except breast cancer screening has been show to reduce morbidity and mortality
- At-risk individuals should pay attention to signs and symptoms
- Lingering aches and illnesses
- Headaches, bone pain, abdominal discomfort
- Surveillance for at-risk children
- Complete physical exam
- Urinalysis
- Complete blood count
- Abdominal ultrasound examination
- Additional organ-targeted surveillance based on family history
- Surveillance for at-risk adults
- Annual complete physical exam including skin, nervous system, rectum, and Pap smear for women
- Consider scans of head and abdomen annually
- Semi-annual clinical breast exam for women
- Annual mammograms, breast ultrasonography, or MRI
- Mammograms controversial because of increased sensitivity to radiation
- Should begin screening by age 25-30
- Additional organ-targeted surveillance based on family history
Differential Diagnosis
edit- Hereditary breast/ovarian cancer syndrome
- Retinoblastoma - Autosomal dominant
- Due to mutations in RB1 gene at 13q14
- RB1 protein is negative regulator of cell growth
- Approximately 90% of retinoblastomas occur before age 3
- Increases risk to develop osteosarcoma 500-fold
- Rothmund-Thomson syndrome - Autosomal recessive
- Due to mutations in RECQL4 gene at 8q24.3 in some families
- Cancer risks increased but not quantified
- Clinical features include:
- Skin atrophy marbleized pigmentation
- Telangiectasia
- Cataracts
- Osteosarcoma is most commonly reported malignancy
- Werner syndrome - Autosomal recessive
- Due to mutations in WRN (RECQL2) gene at 8p12
- Cancer risk is 10% lifetime
- Clinical features include:
- Multiple complaints of problems associated with aging beginning in 20's and 30's
- Cataracts, graying hair or balding, decreased muscle mass, arteriosclerosis, scleroderma, endocrine failure, and NIDDM
- Also may have lack of growth spurt in puberty or dysmorphic features
- Increased risk for osteosarcoma, soft-tissue sarcoma, melanoma, thyroid cancer, and hematological malignancies
- Multiple complaints of problems associated with aging beginning in 20's and 30's
References
edit- Hillmann A, et al. "Familial Occurrence of Osteosarcoma: A Case Report and Review of the Literature." J Cancer
- Res Clin Oncol (2000) 126: 497-502.
- "Li-Fraumeni Syndrome." GeneReviews. http://www.genereviews.org
- Lindor NM, et al. "The Concise Handbook of Family Cancer Syndromes." Journal of the National Cancer Institute (1998) 90(14): 1039-1071.
- "Osteosarcoma/Malignant Fibrous Histiocytoma of Bone." National Cancer Institute. http://www.cancer.gov
- Schneider, Katherine. Counseling about Cancer: Strategies for Genetic Counseling (2002).
- www.lfsassociation.org
Notes
editThe information in this outline was last updated in Nov 2002.